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Abstract
Introduction: Glycoprotein IIb/IIIa inhibitors are recommended by guidelines in patients with ST-segment elevation
myocardial infarction treated with primary percutaneous coronary intervention. There are few studies directly comparing
these agents. The aim of this study was to assess whether eptifibatide is a safe and cost-effective alternative to abciximab in
the treatment of primary percutaneous coronary intervention for ST-segment elevation myocardial infarction.
Methods: This was an observational cohort study of 3863 patients who received a GPIIb/IIIa inhibitor whilst undergoing
primary percutaneous coronary intervention from 2007 to 2014. Patients who did not receive a GPIIb/IIIa inhibitor were
excluded. Time to first major adverse cardiac event defined as death, non-fatal myocardial infarction, stroke or target
vessel revascularization, and total hospital costs were compared between the groups.
Results: In all, 1741 patients received abciximab with 2122 receiving eptifibatide. Patients who received eptifibatide had
higher rates of previous MI/percutaneous coronary intervention and were more likely to undergo a procedure from the
radial route. Unadjusted Kaplan–Meier analysis revealed no significant difference in the 1-year event rates between patients
given eptifibatide versus abciximab (p¼ 0.201). Age-adjusted Cox analysis demonstrated no difference in 1-year outcome
between abciximab and eptifibatide (hazard ratio: 0.83; 95% confidence interval: 0.73–1.39), which persisted after multi-
variate adjustment (hazard ratio: 0.92; 95% confidence interval: 0.79–1.56) including the incorporation of a propensity
score (hazard ratio: 0.88; 95% confidence interval: 0.71–1.44). Eptifbatide was associated with significant cost savings being
87% cheaper overall compared to abciximab (on average £650 cheaper per patient and saving approximately £950,000).
Conclusion: This observational data suggest that eptifibatide is associated with similar outcomes and significant cost
savings compared to abciximab when used in patients with ST-segment elevation myocardial infarction undergoing
primary percutaneous coronary intervention.
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Background
Advances in anti-platelet treatment for acute myocar-
dial infarction (AMI) with the introduction of ticagre-
lor1 and prasugrel2 have improved outcomes after
primary percutaneous coronary intervention (PCI)
with guidelines recommending their use.3 However,
recent emerging data suggest that the administration
of morphine, a commonly used analgesic during AMI
can impair the absorption and delay the onset of action
of ADP receptor antagonist drugs.4,5 This has lead to
the suggestion of the need for strategies such as adjunc-
tive pharmacology to overcome or at least diminish
the negative impact of morphine on these anti-
platelet effects of oral P2Y12 receptor inhibitors.6
Glycoprotein IIb/IIIa inhibitors have been used as
adjuncts for primary PCI for many years but have
fallen out of fashion throughout the UK and Europe
due to the use of these newer anti-platelet drugs.
The most commonly used GPIIb/IIIa inhibitor is
abciximab,7,8 with some contemporary data supporting
its use as a bridging strategy in the morphine era; how-
ever, it is still relatively expensive and emerging data
suggest comparability of eptifibatide.9–13 We therefore
conducted a quality improvement study at our institu-
tion switching from abciximab to eptifibatide in order
to determine whether eptifibatide provides a safe, effec-
tive and cost-effective alternative to abciximab in the
treatment of primary PCI for ST-segment elevation
myocardial infarction (STEMI) and providing further
data for its use as a bridging agent if morphine is used.
Methods
Study design
The study population was derived from a high-volume,
single centre registry of all patients undergoing primary
PCI for acute STEMI between January 2006 and
December 2014. In 2010, we switched from abciximab
to eptifibatide as the first line GPIIb/IIIa inhibitor
administered at our institution. This was done follow-
ing a thorough literature review of available random-
ized/observational data, discussion with management
and based upon the significantly lower cost of eptifiba-
tide compared to abciximab. This study was performed
following this switch between GPIIb/IIIa inhibitors. It
therefore included 3863 consecutive patients receiving
either abciximab (n¼ 1741) (pre-2010) or eptifibatide
(n¼ 2122) (post-2010) as adjunctive therapy between
2006 and 2014. Patients who did not receive a GPIIb/
III inhibitor were excluded. Barts Health Heart Attack
Centre is the only tertiary centre for the North-east
region of London and took all patients with AMI for
primary PCI in an unselected manner. This included
patients with cardiogenic shock and post cardiac
arrest, including intubated and ventilated patients.
Abciximab was administered as an intravenous bolus
of 0.25 mg/kg before/at the start of primary PCI fol-
lowed by a continuous infusion of 0.125 mg/kg/min
(to a maximum of 10 mg/min) for 12 h. Eptifibatide
was administered as an intravenous bolus of 180 mg/kg
at the start of primary PCI followed by a continuous
infusion of 2.0 mg/kg/min for 12 h following the proce-
dure. Contraindications for glycoprotein IIb/IIIa inhib-
itor were in accordance with summary of product
characteristics14,15 and included previous major gastro-
intestinal bleeding, previous haemorrhagic stroke,
chronic renal impairment, thrombocytopenia and con-
current anticoagulant use. Glycoprotein IIb/IIa inhibi-
tor infusions were stopped if there was an adverse
reaction, reduction in platelet count from baseline of
>50%, minor or major bleeding according to the
TIMI bleeding criteria. Standard PPCI protocol for
our institution includes pre-loading with 300 mg aspirin,
300 mg (pre-2007) or 600 mg clopidogrel (post-2007)
and a bolus of GPIIb/IIIA inhibitors unless contraindi-
cated. All patients were prescribed 75 mg aspirin and
75 mg clopidogrel maintenance therapy. Clopidogrel
maintenance therapy was recommended for 1-year
post primary PCI. Aspiration thrombectomy was per-
formed at the operator’s discretion. Successful primary
PCI result was defined as final TIMI (Thrombolysis
In Myocardial Infarction) flow grade 3 and residual ste-
nosis <20% in the infarct-related artery at the end of
the procedure.
Data were prospectively entered onto the local
database at the time of primary PCI. Data collected
included patient characteristics (age, sex, history of
hypertension, hypercholesterolaemia, diabetes mellitus,
smoking status, previous myocardial infarction, previ-
ous PCI, previous coronary artery bypass graft
(CABG), left ventricular ejection fraction and baseline
cardiogenic shock), procedural factors included access
site, culprit vessel, number of diseased vessels, number
of vessels treated, stent type, TIMI flow pre-procedure,
TIMI flow post-procedure and procedural complica-
tions (including myocardial infarction, emergency
CABG, arterial complications and arrthymias requiring
DC cardioversion). Further inpatient complications,
post-discharge complications and further revascularisa-
tion were documented retrospectively using the electron-
ic patient record.
The primary effectiveness end-point was the first
major adverse cardiac event (MACE) defined as
death, non-fatal myocardial infarction or target vessel
revascularization.
Secondary end-points were in-hospital PCI-related
bleeding, categorised by the TIMI bleeding criteria
and cost per patient. MACE events (identified from
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patient notes and electronic records) were adjudicated
by three independent physicians who were not involved
in the procedure and were unaware of the patient’s
GPIIb/IIIa type. All-cause mortality data were
recorded as of the 12 September 2015 and obtained
via the British Cardiovascular Intervention Society-
UK Central Cardiac Audit Database (CCAD). This
national database is periodically linked to the UK
Office of National Statistics and provides live/death
status of treated patients. Only patients who had com-
plete database records and National Health Service
unique numbers (allowing live/death status to be
assessed) were included in the analysis. A retrospective
data quality audit of 100 randomly selected medical
records established that 94.8% of data fields, including
complications, were entered correctly into the database.
Cost-effectiveness
The cost of eptifibatide and abciximab per patient were
calculated based on the standard drug dosages and
protocols from Epistent, Pursuit and PrismPlus trials,
respectively (Table 1) and based on the unit prices
given in the British National Formulary (BNF)
(Table 2). The average cost per patient and the total
savings made by the switch were calculated.
Ethics
The data were collected as part of a mandatory nation-
al cardiac audit and all patient identifiable fields were
removed prior to analysis. The local ethics committee
advised us that formal ethical approval was not
required.
Statistical analysis
Clinical characteristics of eptifibatide- versus
abciximab-treated patients were compared using the
Pearson Chi Square test for categorical variables and
Student t test for continuous variables. Normality of
distribution was assessed using the Shapiro–Wilks test.
We calculated Kaplan–Meier product limits for
cumulative probability of reaching an end point and
used the log rank test for evidence of a statistically
significant difference between the groups. Time was
measured from the first admission for a procedure to
outcome (all cause mortality). Cox regression analysis
was used to estimate hazard ratios (HRs) for the effect
of GPIIb/IIIa inhibitor type in age-adjusted and
fully adjusted models, based on covariates (p< 0.05)
associated with the outcome. The proportional hazards
assumption was evaluated by examining log (log) sur-
vival curves and additionally was tested with
Schoenfield’s residuals. The proportional hazard
assumption was satisfied for all outcomes evaluated.
Cox analysis was performed both with and without
year of procedure as a covariate to correct for any
time-related effect during the study period.
A propensity score analysis was carried out using a
non-parsimonious logistic regression model comparing
abciximab and eptifibatide patients. Multiple variables
were included in the model, including age, gender, dia-
betes, hypertension, hypercholesterolaemia, previous
CABG, previous PCI, previous MI, multivessel disease,
chronic renal failure, pre-procedure TIMI flow, ejec-
tion fraction and procedural success. C-Score was
0.81 indicating good discrimination. After ranking pro-
pensity score in an ascending order, a nearest neigh-
bour 1:1 matching algorithm was used with callipers of
0.2 standard deviations of the logit of the propensity
score. Each abciximab and eptifibatide patient was
used in at most one matched pair to create a matched





dose (70 kg patient)
Costa (rounded
to full vials)
Abciximab 0.25 mg/kg 10 min before PCI 0.125 mg/kg/min
(10 mg/min)
12 24.7 mg £750.72
Eptifibatide 180 mg/kg 10 min before PCI 2 mg/kg/min 18 151 mg £99.19
Tirofiban 0.4 mg/kg/min for 30 min, starting
10 min before PCI
0.10 mg/kg/min 18 8.4 mg £146.11
aBased on unit prices given in Table 3 below.
PCI: percutaneous coronary intervention.





Tirofiban (Aggrastat) £146.11 50mg/ml–250ml bag





aBNF September 2014–March 2015.
BNF: British National Formulary.
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sample with similar distribution of baseline character-
istics between observed groups. Based on the matched
samples, cox proportional hazard model was used to
determine the impact of GPIIb/IIIa inhibitor on mor-
tality over follow-up. STATA version 10 and
Graphpad Prism version 5 were used for all analysis.
Results
During the study period, there were 4829 patients pre-
senting with a STEMI. Of these patients, 3863 (80.0%)
received a GPIIb/IIIa inhibitor as adjunctive therapy
for primary PCI. In all, 1741 patients received abcix-
imab and 2122 patients received eptifibatide.
Patient characteristics (Table 3)
With respect to baseline characteristics, the two groups
were well balanced. The mean age in the eptifibatide
group was 63.88 14.1 and 62.10 16.1 in the abcix-
imab group. The majority of the patients were male in
both groups (76.2% in the eptifibatide group and
77.1% in the abciximab group). Patients in the eptifi-
batide group were more likely to have had a previous
myocardial infarction (16.9% vs 12.8% and undergone
previous PCI compared with patients receiving abcix-
imab (12.8% and 9.4%, p¼ 0.028). There was also a
higher prevalence of hypercholesterolaemia in the epti-
fibatide group compared with the abciximab group
(53.1% versus 42.4%, respectively, p< 0.001). Similar
rates of morphine use were seen in the two groups.
Procedural characteristics (Table 4)
Patients treated with eptifibatide were significantly
more likely to undergo the procedure via the radial
route receive intervention to the LAD and have
multi-vessel intervention. They were also more likely
to undergo PCI with drug-eluting stents.
Procedural outcome (Table 5)
There were similar rates of procedural success achieved
in the two groups (93.4% of the eptifibatide group vs
92.4% of the abciximab group). There were no signif-
icant differences between the groups for in-hospital
MACE or any of its components (MI/emergency
bypass surgery/death). Additionally, there was no dif-
ference in the rates of any procedural complication
between the groups.
Bleeding (Table 5)
No difference in rates of either major (3.1% of the
eptifibatide group versus 5.4% of the abciximab
group, p¼ 0.08) or minor bleeding (4.5% of the eptifi-
batide group versus 5.1% of the abciximab group,
p¼ 0.45) were seen between the two groups.
Follow-up (Figure 1)
Unadjusted Kaplan–Meier analysis revealed no signif-
icant difference in MACE rates over the follow-up
period between patients given eptifibatide versus




(n¼ 2122) P value
Age 62.10 16.1 63.88 14.1 0.098
Gender (female) 432 (24.8%) 486 (22.9%) 0.382
Previous MI 223 (12.8%) 359 (16.9%) 0.041
Previous CABG 71 (4.1%) 57 (2.7%) 0.114
Previous PCI 164 (9.4%) 272 (12.8%) 0.028
Hypercholesterolaemia 924 (53.1%) 900 (42.4%) <0.001
Hypertension 810 (46.5%) 955 (45.0%) 0.546
DM 313 (18.0%) 378 (17.8%) 0.947
eGFR< 60 346 (19.9%) 439 (20.7%) 0.851
MV disease 985 (56.6%) 1216 (57.3%) 0.686
Card shock 91 (5.2%) 134 (6.3%) 0.404
Procedural success 1626 (92.4%) 1961 (93.4%) 0.139
Morphine use 1017 (58.4%) 1210 (57.0%) 0.560
MI: myocardial infarction; CABG: coronary artery bypass graft; PCI:
percutaneous coronary intervention; DM: diabetes mellitus; eGFR: esti-
mated glomerular filtration rate; MV: multivessel.
*p value< 0.05.









Radial 723 (41.5%) 1233 (58.1%) 0.001
Femoral 1018 (58.5%) 889 (41.9%) 0.001
Target vessel 0.027
Right coronary artery 750 (43.1%) 893 (42.1%)
Left main coronary
artery
14 (0.8%) 23 (1.1%)
LAD 770 (44.2%) 1074 (50.6%)
Left circumflex
coronary artery
204 (11.7%) 214 (10.1%)
Saphenous vein graft 16 (0.9%) 21 (1.0%)
Door to balloon
time (min)
39 (25–80) 45 (30–89) 0.120
Symptom to balloon
time (min)
175 (108–312) 181 (112–358) 0.230
Multivessel Intervention 369 (21.2%) 679 (32.0%) 0.080
Thrombectomy use 432 (24.8%) 541 (25.5%) 0.289
Drug-eluting stent use 1475 (84.7%) 1630 (76.8%) 0.031
Procedural success 1609 (92.4%) 1982 (93.4%) 0.622
LAD: left anterior descending.
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abciximab (18.4% vs 19.2%, p¼ 0.121). The pattern
was similar for all MACE components including all
cause mortality, recurrent myocardial infarction and
target vessel revascularisation.
Unadjusted and multivariate analysis
Age-adjusted Cox analysis demonstrated no difference
in outcomes after the follow-up period between abcix-
imab and eptifibatide (HR: 0.83; 95% confidence inter-
val (CI): 0.73–1.39), which persisted after multivariate
adjustment (HR: 0.92; 95% CI: 0.79–1.26). In addition,
after regression adjustment incorporating a propensity
score (age, gender, ethnicity, previous MI, PCI or
CABG, diabetes, hypertension, hypercholesterolaemia,
smoking status, presence or absence of shock and ejec-
tion fraction) into the hazards model as a covariate, no
difference in outcome emerged (HR: 0.88; 95% CI:
0.71–1.24) (Figure 2).
The above Cox proportional hazard model was
repeated with the year of procedure included as a cate-
gorical variable to allow for improvements in PCI tech-
nique and technology over the long study period. This
confirmed no association between GPIIb/IIIa inhibitor
type and MACE (HR: 0.85; 95% CI: 0.73–1.22).
Propensity score
To further account for confounding variables and bias,
propensity score matching was performed to adjust for
differences in demographic and procedural variables
producing a total of 2882 patients (1441 in the eptifiba-
tide group and 1441 in the abciximab group).
Following matching the baseline demographics and
procedural variables were well balanced in the two
propensity-matched cohorts. In the propensity-
matched cohorts, Cox regression analysis revealed
that GPIIb/IIIa inhibitor type was not a predictor of
MACE (HR: 0.82; 95% CI: 0.60–1.13).
Cost data
Looking at the cost comparisons between the two
agents, the average cost per patient treated with abcix-
imab based on a unit cost of each treatment (£250.24) is
£750.72. The average cost per patient treated with epti-
fibatide based on a unit cost of each treatment (£42.79/
13.61) is £99.19. No difference was seen in clinical out-
comes or length of stay between the two agents result-
ing in a cost comparison based on the price of the
agent. For the propensity-matched cohorts of 1441
patients, the total cost of abciximab was £1,081,787
compared to £142,933 for eptifibatide meaning an
87% cost saving of £938,854 made with the switch to
eptifibatide over the study period.
Discussion
This is the largest observational study performed to
date comparing the cost-effectiveness and use of eptifi-
batide as an alternative to abciximab in primary PCI
for STEMI. The results demonstrated the usefulness
and safety of these agents in primary PCI demonstrat-
ing similar effectiveness for both therapies with com-
parable procedural success rates, unadjusted and
adjusted outcomes at 1 year and over the follow-up
period. Importantly, the switch from abciximab to epti-
fibatide resulted in significant cost savings for the insti-
tution with an average of £650 per patient and a total
saving of approximately £950,000. This provides
important data to guide the choice of GPIIb/IIIa





(n¼ 2122) p Value
In Hospital
MACE 56 (3.2%) 53 (2.5%) 0.070
Death 33 (1.9%) 36 (1.7%) 0.098
Re-infarction 7 (0.4%) 6 (0.3%) 0.310
Re-intervention PCI 5 (0.3%) 4 (0.2%) 0.650
Cerebrovascular Accident 9 (0.5%) 6 (0.3%) 0.411
Emergency CABG 1 (0.1%) 0 (0%) 0.411
Stent thrombosis 8 (0.4%) 10 (0.5%) 0.699
Bleeding
Major 894 (5.4%) 66 (3.1%) 0.08
Minor 89 (5.1%) 95 (4.5%) 0.45
MACE: major adverse cardiac event; PCI: percutaneous coronary inter-
vention; CABG: coronary artery bypass graft.
Figure 1. Kaplan–Meier curves showing cumulative probability
of major adverse cardiac events after primary PCI according to
GPIIb/IIIa type.
PCI: percutaneous coronary intervention.
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inhibitor to be used in current practice, especially
giving increasing concerns over the absorption of
newer drugs.
Abciximab is by far the best studied GP IIb/IIIa
inhibitor in patients with primary PCI, with studies
demonstrating reduced rates of death, MI and TVR
compared to placebo,16,17 with its use in contemporary
practice demonstrating negation of the effects of mor-
phine on platelets.6 Eptifibatide also has proven clinical
benefit, although this agent has been mostly studied in
patients with stable coronary artery disease undergoing
PCI.18 Until recently, there were few direct compari-
sons between abciximab and eptifibatide in the setting
of primary PCI. In the Eptifibatide Versus Abciximab
in Primary PCI for Acute Myocardial Infarction
(EVA-AMI) trial, 427 patients who underwent primary
PCI were randomized to receive eptifibatide or abcix-
imab showed no statistically significant difference
between the two agents with respect to the primary out-
come of ST-segment resolution, with the study not pow-
ered to compare clinical end points.10 Similar findings
were found in a sub-group analysis of HORIZONS-
AMI, three registries and in a meta-analysis comparing
eptifibatide and abciximab.9,11,19
There are key pharmacological differences between
abciximab and eptifibatide, which may result in differ-
ences in outcome. Abciximab is an irreversibly inhibit-
ing monoclonal antibody Fab fragment, which has a
short plasma half-life (30 min), but a disassociation
half-time of 18–24 h meaning abciximab can result in
increased bleeding due to persistent platelet inhibition
several days after medication discontinuation.20
However, eptifibatide, which provides reversible, com-
petitive, dose-dependent inhibition of GP IIb/IIIa
receptors with a short half-life of about 2.5 h, and nor-
malization of platelet aggregation approximately 4
h after drug cessation.21,22 These factors suggest that
eptifibatide may be associated with lower bleeding rates
or at least less severe bleeding rates than abciximab due
to this quicker resolution of platelet inhibition. This
was supported by data in our study where a trend to
lower bleeding rates were seen in the eptifibatide group.
Furthermore, it is worth noting that although this
lower bleeding rate in the eptifibatide group was not
statistically significant, there was a significantly higher
rate of radial access in the abciximab group and it is
possible that if the rates of femoral access were similar
between the two groups, this bleeding difference could
be significant. These features make eptifibatide an ideal
agent to use in conjunction with newer P2Y12 inhibi-
tors whilst waiting levels to reach steady state.
Limitations of the current study
Our study is a consecutive but retrospective observa-
tional analysis from a single centre’s experience. As this
Figure 2. Multivariate Cox regression analysis for hazard of all-cause mortality after percutaneous coronary intervention.
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was an observational study, the findings may have been
subject to confounding factors that we have been
unable to control for. This may include adherence to
evidence based therapies, e.g. medication, which has
been shown to be associated with outcome. However,
our dataset includes all major clinical variables known
to affect outcome, which would support the validity of
our results.
Conclusion
This observational study suggests that eptifibatide is
associated with similar clinical outcomes and is associ-
ated with significant cost savings compared to abcixi-
mab in patients with STEMI undergoing primary PCI.
These agents should still be considered as adjunctive
therapies for primary PCI especially if concerns exist
over the absorption of oral anti-platelet drugs.
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